Chinese biotech startup Allink Biotherapeutics, which counts China’s publicly listed Junshi Biosciences among its angel investors, has closed a $42-million Series A round to fund the global clinical studies of its pipeline products, it announced on Thursday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
